This phase Ib/II trial studies the side effects and best dose of venetoclax and how well it works when given together with ivosidenib with or without azacitidine, in treating patients with IDH1-mutated hematologic malignancies. Venetoclax and ivosidenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ivosidenib and venetoclax with azacitidine may work better in treating patients with hematologic malignancies compared to ivosidenib and venetoclax alone.
Age > 18 years.
ECOG performance status of < 2.
IDH1-R132 mutated disease status as assessed by local laboratory. 2HG-producing IDH1 variants outside of R132 (i.e. R100) may be eligible after discussion with the PI.
Relapsed/refractory AML, or treatment-naïve patients with AML who are not eligible for standard induction chemotherapy. Patients with high-risk MDS, MDS/MPN or MPN (defined as > 10% bone marrow blasts, or intermediate or high risk by IPSS, R-IPSS or D-IPSS) that have failed standard therapy may also be eligible after discussion with the PI.
Patients with known allergy or hypersensitivity to ivosidenib or venetoclax.
Patients who have previously received either ivosidenib or venetoclax.
Patients with any concurrent uncontrolled clinically significant medical condition including infection, laboratory abnormality, or psychiatric illness, which could place the patient at unacceptable risk of study treatment.
The use of other chemotherapeutic agents or anti-leukemic agents is not permitted during study with the following exceptions (1) intrathecal chemotherapy for prophylactic use or for controlled CNS leukemia. (2) use of hydroxyurea and/or one dose of cytarabine (up to 2 g/m2) for patients with rapidly proliferative disease is allowed before the start of study therapy and for the first four weeks on therapy.
Single group
Azacitidine
DrugGiven IV or SC
Ivosidenib
DrugGiven PO
Venetoclax
DrugGiven PO
Overall response rate (ORR)
Defined as complete response (CR), CR with incomplete blood count recovery (CRi), morphologic leukemia-free state (MLFS), and partial response (PR) based on revised International Working Group (IWG) response criteria. Analysis will be performed for enrolled subjects.
Incidence of adverse events
Will be collected using leukemia adverse event guidelines.
Dose-limiting toxicity
Defined as any grade 3 or 4, clinically significant non-hematologic adverse event or abnormal laboratory value.
Response to therapy
Will be calculated.
Duration of response
Will be calculated.
Event-free survival
Will be calculated.
Overall survival
Will be calculated.
Plasma concentrations and pharmacokinetic parameter
Will be tabulated for each subject, visit, and dose level, and summary statistics will be computed for each sampling time and each parameter.
Peripheral blood and bone marrow aspirate samples
Biomarker assays may include, but are not limited to, BH3 profiling and characterization of BCL-2 and related proteins, IDH1 mutant status, serum R-2HG analysis, and assessment of the depth of response and monitoring of disease recurrence by assessment of minimal residual disease in the bone marrow.
Click on the lead sponsor to view all of their trials.
